Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,070 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hematopoietic Stem Cell Transplantations Clear all
Completed Phase 1 Interventional

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

NCT00434629
View directory record Official record
Conditions
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bexxar
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients

NCT04423939
View directory record Official record
Conditions
Hematopoietic Steam Cell Transplantation (HCT)
Interventions
Acceptance and Commitment Therapy (ACT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

NCT00053989
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Fanconi Anemia, Aplastic Anemia
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome

NCT01287078
View directory record Official record
Conditions
Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 1 Interventional

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

NCT01627275
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Naive T Cell Depleted Donor Lymphocyte Infusion
Biological
Lead sponsor
Mitchell Horwitz, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Melphalan in Children

NCT02390544
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Melphalan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 16, 2026, 10:44 AM EDT
Completed No phase listed Observational

Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database

NCT01353677
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
2 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Gainesville, Florida • Rochester, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 1 Interventional

Sickle Cell Disease Conditioning for Bone Marrow Transplant

NCT00968162
View directory record Official record
Conditions
Bone Marrow Transplantation, Sickle Cell Disease
Interventions
fludarabine
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

NCT00002942
View directory record Official record
Conditions
Breast Cancer
Interventions
autologous bone marrow transplantation, peripheral blood stem cell transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 16, 2026, 10:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

NCT04959903
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Allogeneic T cell progenitors, cultured ex-vivo
Biological
Lead sponsor
Smart Immune SAS
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 16, 2026, 10:44 AM EDT
Recruiting Phase 2 Interventional

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Recruiting Phase 2 Interventional

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

NCT06799195
View directory record Official record
Conditions
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Interventions
Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus, Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Recruiting Early Phase 1 Interventional

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

NCT07244419
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Graft Failure
Interventions
Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Completed No phase listed Observational

Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant

NCT00179075
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 15, 2008 · Synced Oct 16, 2026, 10:44 AM EDT
Recruiting Early Phase 1 Interventional

T Cell Therapy of Opportunistic Cytomegalovirus Infection

NCT02982902
View directory record Official record
Conditions
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections
Interventions
CMV specific adoptive t-cells
Biological
Lead sponsor
Mari Dallas
Other
Eligibility
3 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

NCT01690143
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Melphalan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 16, 2026, 10:44 AM EDT
Active, not recruiting Phase 1 Interventional

Inqovi Maintenance Therapy in Myeloid Neoplasms

NCT04980404
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia
Interventions
Inqovi
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Completed No phase listed Observational

Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

NCT02064933
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Early Phase 1 Interventional

Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies

NCT00013533
View directory record Official record
Conditions
Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome, Non Hodgkin's Lymphoma, CML, ALL, AML, Lymphoma
Interventions
Stem cell transplantation
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 16, 2026, 10:44 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07702578
View directory record Official record
Conditions
AML, MDS
Interventions
TSC-101, Control
Drug · Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
26
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

NCT07675174
View directory record Official record
Conditions
GVHD - Graft-Versus-Host Disease
Interventions
Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

NCT03104491
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
Inotuzumab Ozogamicin
Drug
Lead sponsor
Leland Metheny
Other
Eligibility
16 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Westwood, Kansas • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

NCT00001623
View directory record Official record
Conditions
Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplant
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 16, 2026, 10:44 AM EDT
Withdrawn Phase 1 Interventional

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
Procedure · Biological · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 10:44 AM EDT